Abstract. Enterovirus 71 (EV71) is a major cause of hand, foot and mouth disease (HFMD); however, no clinically approved vaccine or antiviral treatment is currently available for EV71 infection. In the present study, a murine model of EV71 infection was constructed. The clinical isolates of EV71 were amplified in Vero cells and used to challenge adult mice via hydrodynamic injection (HI) and intraperitoneal injection (IP). Following two challenges, >50% of the mice succumbed to EV71 infection. Surviving female mice were identified to have impaired fertility and their litter sizes were significantly decreased compared with the control group. The antibody against EV71-VP1 persisted in the sera of female mice at a high titer for >2 years after challenge. The maternal antibody in the offspring sera also persisted for ~1 year and disappeared after ~2 years. Results from the present study suggest that a high titer of active EV71 was able to impair the reproductivity of adult female mice, and that high levels of maternal antibody persisted in the offspring and protected postnatal mice from EV71-induced mortality. The promising antigenicity, immunogenicity and reactogenicity of EV71 suggests that it a potential vaccine target that may be beneficial to the control of HFMD, through immunizing infants and women of reproductive age.
Introduction
Enterovirus (EV) 71 is a member of the picornaviridae family of viruses that contain single-stranded positive-sense RNA (1) , which primarily infects children <5 years old (2) . Infants with EV71 infection develop sores on their hands, feet, buttocks and mouth; therefore, the infection is referred to as hand, foot and mouth disease (HFMD) (3) . Several types of enterovirus have been indicated to cause HFMD in children; however, EV71 is commonly associated with severe complications of the nervous system in infants with HFMD and is therefore considered to be a major virulent pathogen and cause of mortalities in HFMD (4) . Previous studies have indicated that a total of 488,955 HFMD cases and 126 HFMD-associated mortalities were reported in 2008 in China, of which EV71 infection was the primary cause (5) . EV71 is a non-enveloped virus with a single-stranded positive-sense RNA genome that is ~7.5 kb in size and belongs to the enterovirus genus of the picornaviridae family (6) . EV71 is classified into five genotypes as follows: A, B, C, D and F, and further subdivided into B0-B5 and C1-C5 subgenotypes (7) . HFMD is an important public health issue and further understanding of the mechanisms underlying the development of HFMD are required to develop effective treatments. In mainland China, Taiwan and Singapore, EV71 whole-virus vaccines have been produced by various manufacturers. Two available inactivated EV71 vaccines have been approved by the China Food and Drug Administration, one produced by Sinovac Biotech Ltd. and the other by the Chinese Academy of Medical Science (all Beijing, China) (8) (9) (10) . Currently, no effective treatment is available to treat severe EV71 infections, aside from symptomatic therapies (11) .
Typically, Vero and RD cell lines have been used to isolate EV71 (12) , and suckling BALB/c mice have been studied to evaluate the virulence and pathogenicity of the isolated strain (13) . A previous study indicated that neonate mice were able to be fatally infected with EV71 from 0-7 days of age, whereas mice >7 days old hardly did not exhibit any symptoms (14) . A similar situation possibly exists in adult humans, which raises various questions, including the following: Whether EV71 may be transmitted from pregnant women with occult EV71 infection to the fetuses; the pathogenic damage that occurs to the fetus when the mother is infected with EV71; and whether the neutralizing antibody for EV71 from a mother may protect her infant.
In the present study, one EV71 strain from a patient with HFMD exhibiting severe neurologic symptoms was isolated and characterized. The strain of EV71 was identified as subgenotype C4a, and was used as the C4 subgenotype has been indicated to be the most prevalent EV71 subgenotype in mainland China (5, 15 Two successive high titer EV71 challenges induced mortality in the majority of the adult mice. Mice that survived were identified to have impaired fertility, and their litter size was significantly reduced compared with the control group. The antibody directed against the VP1 conserved region of EV71 persisted in female murine sera at a high titer for >2 years after challenge. The maternal antibody in the sera of the offspring murine also persisted for ~1 year at a moderate titer and disappeared after ~2 years. cells per well) as previously described (5, 15) . EV71 strains in the culture supernatant were harvested by thawing and refreezing based upon the appearance of cytopathic effects, such as pyknosis, turning round, and floating in the medium. Following propagation by cell culture and identification using the plaque assay (described below), the EV71 virus stock was adjusted to 1.0x10 7 pfu and used as the parental virus in all assays (16) .
Materials and methods
Serum cytokine and chemokine detection. Cytokines and chemokines in the sera (10 µl) from EV71-infected mice were quantitatively measured by FLEXMAP 3D quantification (Luminex Corporation, Austin, TX, USA) as described previously (17) . A series of cytokines, including interleukin (IL) 1-α, 1β, 2, 3, 4, 5, 6, 10, 17F and 21, 12p40, 12p70, 17A, 13, 23p19, interferon-γ-inducible protein 10 (IP-10), keratinocyte chemoattractant (KC)/chemokine C-X-X moftif ligand 1 (CXCL1), interferon-γ, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor (TNF)-α, eotaxin and monocyte chemoattractant protein (MCP)-1, were detected using Milliplex MAP kits (cat. no. RCYTO-80K; EMD Millipore, Billerica, MA, USA), which were used in combination as described previously (17) . The mean of ≥2 independent measurements was calculated using xPONENT software version 3.1 (Luminex Corporation).
Plaque assay. Viruses in samples were routinely amplified by passaging the swab-derived virus through the RD cells for one round (24 h) prior to reinfection with Vero cells for the plaque assay. Virus stock was produced by harvesting the supernatant of EV71-infected-Vero cells. Virus titer and morphology were determined via a bilayer plaque assay (16) . A series of 1:10 dilutions were prepared by diluting 15 ml virus stock with 135 ml DMEM supplemented with 10% FBS, and 100 ml of each dilution was seeded into each well of a 6-well plate containing confluent Vero cells (1x10 6 cells/well; plated 1 day in advance) as described previously (18) . Plates were incubated at 37˚C for 1 h before the first layer of 1.2% agar was added. After 72 h of incubation at 37˚C, a second layer of 1.2% agar containing the neutral red pH indicator was added. Following incubation at 37˚C for 12-24 h, images of the plaques were captured and the number of formed plaques was determined as described previously (16, 18) . The viral titer was calculated as pfu/ml. The limit of detection was 10 pfu/ml.
Determination of viral titers in the tissue and serum samples of infected mice.
A total of 100 female ICR mice (8-10 weeks old; 20.36±1.31 g) were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China) and maintained under specific pathogen-free conditions (22-26˚C, 40-70% humidity, 10 h light and 14 h dark per day) in the Central Animal Laboratory of Shaoxing Hospital of Zhejiang University. Mice were housed in cages with a bevel allowing free access to food and water. A total of 12 mice (6 per group) were challenged with l ml EV71 (1x10 7 pfu/ml) via HI or IP. Mice were sacrificed by cervical dislocation 24 or 48 h post injection (19, 20) . Blood samples were collected from the orbital vein, and organs and tissues were harvested after systemic perfusion with 50 ml sterile PBS. The organs and tissues were weighed and then homogenized in PBS using a mechanical homogenizer, and disrupted by three freeze-thaw cycles after sacrifice, as described previously (21) . Subsequently, viral titers in the supernatants of purified homogenates of the liver, brain, kidney, heart, spleen and lung, together with blood, were quantified by reverse transcription-quantitative PCR (RT-qPCR) analysis.
RNA extraction and RT-qPCR. For RT-qPCR, viral RNA was extracted from fresh murine tissue homogenates, the blood, and throat and anal samples using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Following digestion with DNase I, extracted RNA was reverse transcribed into cDNA using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) and oligo-d(T) primers according to the manufacturer's instructions. The following primers were designed to target the VP1 conserved region of EV71: Forward, 5'-GCA GCC CAA AAG AAC TTC AC-3' and reverse, 5'-ATT TCA GCA GCT TGG AGTGC-3'. RT-qPCR was performed for 40 cycles as follows: 95˚C for 5 sec, 55˚C for 15 sec and 72˚C for 9 sec using an Mx3005P machine (Agilent Technologies, Inc., Santa Clara, CA, USA) as previously described (5, 15) . The final reaction volume was 25 µl, including 1 µl each of forward and reverse primers, 5 µl 5X reaction buffer, 5 µl sample as template, 1 µl DNA polymerase and 12 µl water. An EV71 reporter virus (GenBank accession no. JN256064; provided by Professor Bo Zhang, Wuhan Institute of Virology, Chinese Academy of Science, China) with whole EV71 sequence was used as a standard to calculate the EV71 copy number as described previously (18) .
Mouse EV71 challenge. A total of 1 ml Vero culture supernatant with isolated EV71 (1.0x10 7 pfu) was quickly injected into the tail veins of mice to maintain high pressure, or into the enterocoelia, as described previously (20) . The control group (6 mice) received the same volume of DMEM. A booster injection was administered 2 weeks following the first injection. Blood samples were harvested 24 and 48 h after the last immunization.
For the lethalality assay, four groups of female ICR mice (6-8 weeks old, 8 mice per group) were challenged with isolated EV71 using HI or IP. Group 1: Primer and boost challenge with active EV71; group 2: Primer challenge with active EV71 and boost with inactive EV71; group 3: Primer challenge with inactive EV71 and boost with active EV71; group 4: Primer challenge with inactive EV71 and boost with inactive EV71. Survival rates were determined using GraphPad Prism software (version 5; GraphPad Prism Software, Inc., La Jolla, CA, USA).
For the reproductive damage assay, 2 groups of female mature ICR mice were challenged with active EV71 (24 mice) or DMEM as control (6 mice) by HI and then raised with male adult ICR mice to conceive. Booster challenge with active EV71 or DMEM was administered to the female mice via IP two weeks post primer challenge. Control group: Primer and boost challenge both with DMEM. 'Once' group: Primer challenge with active EV71 and boost with DMEM. 'Twice' group: Primer and boost challenge both with active EV71. The litter size of all surviving female mice after birth was noted and used for the assessment of reproductive ability.
For evaluation of the protectiveness of maternal antibody, 1-day-old ICR neonatal mice (weight, 1.8-2.0 g) born from the EV71-challenged and mock mice were challenged with 50 µl active EV71 or DMEM via intracranial injection as previously described (22, 23) . All mice were monitored for clinical symptoms, paralysis, and death for at least 14 days post-injection. In addition, for dynamic regularity of EV71-VP1-IgG, the EV71-challenged maternal mice and their second generation mice were randomly allocated into 2 groups of 10 mice, and were monitored daily for clinical signs of infection, including ruffled hair, hunched back, paralysis and mortality until the end of the assay (120 weeks), as described previously (22) .
Statistical analysis. Statistical analysis was performed using GraphPad Prism software (version 5; GraphPad Prism Software, Inc.). The significance of all differences in multiple comparisons were determined using the Student's t-test. Results are presented as the mean ± standard deviation of three independent experiments. P<0.05 was considered to indicate a statistically significant difference.
Results
Characterization of the isolated EV71 strain. The EV71 strain used as virus stock in the present study was isolated from clinical samples from children with HFMD. The viruses infected Vero cells, inducing typical CPE as shown in Fig. 1A-D . In a previous study by the present authors, the VP1 sequence of this Figure 1 . Viral titer and morphology of EV71 isolates from clinical specimens was determined using a bilayer plaque assay. EV71-positive samples identified by reverse-transcription-quantitative polymerase chain reaction were used to inoculate Vero cells and images were captured after (A) 24, (B) 48, (C) 72 and (D) 96 h. Virus stock produced by harvesting Vero cell supernatant after characteristic cytopathic effects were observed. Virus titer and morphology were determined using a bilayer plaque assay. A series of 1:10 dilutions were administered by diluting 15 ml virus stock with 135 ml medium: (E) 1x10 2 , (F) 1x10 3 (G 1x10 4 (H) 1x10 5 and (I) 1x10 6 dilution fold. A total of 100 ml of each mixture was added into each well of a 6-well plate seeded with confluent Vero cells. EV71, enterovirus 71. isolated EV71 strain was amplified, sequenced, aligned, and was identified to be of the C4a genotype (5, 15) .
Virus stock was produced by harvesting the supernatant of EV71-infected Vero cells. Virus titer and morphology were determined using a bilayer plaque assay (Fig. 1E-I) . A total of 21 plaques were identified in the well with a 1x10 5 dilution (Fig. 1H) . The virus solution with a titer of 2.1x10 7 was adjusted to 1x10 7 and used as the parental virus in all assays.
EV71 challenge with HI produces a higher viral titer in the tissue compared with IP.
In order to achieve a higher titer EV71 in the tissue of mice, administration of EV71 by HI and IP was compared. Tissue samples were homogenized in sterile PBS, disrupted by three freeze-thaw cycles and centrifuged at 14,000 x g. EV71 copy number was calculated by RT-qPCR. As indicated in Fig. 2A and B, administration via HI resulted in a significantly increased EV71 titer compared with IP at 24 and 48 h after injection (P<0.05), which indicated that HI was preferable for acquiring a high viral titer in the tissue and blood.
EV71 challenge is fatal to adult mice. Groups of female ICR mice were challenged with isolated EV71 via HI or IP. Four h post booster injection, a total of 80% of mice succumbed to EV71 infection as a result of primer and booster challenge (Fig. 3A) , 40% of mice succumbed to EV71 when first challenged with active EV71 and then receiving inactive EV71 as a booster (Fig. 3B) , 80% of mice survived when first challenged with inactive EV71 and then receiving active EV71 as a booster (Fig. 3C ) and 90% of mice survived when treated with inactive EV71 as a primer and booster (Fig. 3D) . It was noted that mortality was highest half an hour post booster injection.
To further investigate why EV71 challenge induced sudden fatality the blood samples from mice that survived primer and booster challenge with active EV71 virus alone were collected and subjected cytokine/chemokine detection. IL-1b, IP-10, IL-6, IL-12, KC/CXCL1, IL-23p19, TNF-α and MCP-1 were significantly upregulated in EV71-challenged mice compared with the non-challenged control group (P<0.01; Fig. 3E ). These results suggest that the fatality of the challenged mice was promoted by potent immunological stress, not the infectivity and virulence of EV71 Furthermore, these findings suggest that active EV71 possesses high antigenicity compared with inactive EV71, which triggers immunoreaction.
EV71 challenge impairs the reproductive capacity of female mice. Female mature ICR mice in the 'Twice' group were challenged with active EV71 by HI before and after pregnancy. A large proportion of the mice succumbed to EV71 infection. Mice that survived were housed under specific pathogen-free conditions in individual ventilated cages until parturition. Mice in the 'Twice' group gave birth to a mean of 5 suckling mice, whereas litter size in the 'Once' group was 12 and in the control group was 14. Active EV71 administered as a primer and/or booster was identified to significantly impair the reproductivity of female mice compared with the control group (P<0.05; Fig. 4A ). A total of 20% of survivors challenged twice with EV71 exhibited neurologic symptoms, including torticollis and walking disorder (Fig. 4B) . A number of neonatal mice produced from female mice challenged with active EV71 presented with abnormalities, including stillbirth and dwarfism. The proportion of abnormalities were in line with the challenge number (Fig. 4C) .
EV71 antibody is maintained at a high titer for a longer duration after challenge with EV71 twice in maternal and postnatal mice. Blood samples were collected from 1-120 after the booster injection and EV71 antibody levels were detected using an ELISA kit. Maternal EV71-VP1 antibody titer reached a peak ~4 weeks after the booster injection and persisted at a high level for ~1 year, following which it slowly declined until the end of monitoring (Fig. 5A ). Maternal antibodies in the blood samples taken from postnatal mice after birth were also monitored. As illustrated in Fig. 5A , the level of EV71-VP1 antibody gradually declined after birth and was barely detectable at the end of monitoring. This maternal antibody was indicated to be protective, as 3-day-old suckling mice with the maternal antibody were challenged with active EV71 by intracranial injection. Mice that were challenged with EV71 and exhibited the maternal antibody had a significantly increased survival rate compared with mice with no maternal antibody; >70% of these mice were protected from EV71-induced fatality compared with 20% of mice without the maternal antibody (P<0.05; Fig. 5B ).
Discussion
HFMD typically occurs in children <5 years old, and EV71 and coxsackie virus A16 have been identified as the primary causes of HFMD (2) . Serious neurological complications and fatalities are associated with EV71 (24) . Due to a lack of effective treatment options, controlling EV71 epidemics has predominantly relied upon the formation of EV71 vaccines (11) . Therefore, effective vaccines that protect against EV71-associated HFMD or herpangina are important (25) . Currently, two monovalent EV71 vaccines have been marketed in mainland China (2) . However, clinical data concerning their effectiveness is not yet available.
Despite the extensive research undertaken since the discovery of EV71, the following issues require further investigation: The potential harm to a pregnant woman with EV71 latent infection and her fetus; and the length of time that anti-EV71 antibody remains effective after vaccination. In the present study, an isolated C4a EV71 strain was used to challenge ICR mice. The results indicated that EV71 was maintained a higher viral titer (calculated by RT-qPCR) in murine tissue and blood when challenged via HI as displayed in Fig. 2A . Furthermore, >50% of the challenged mice succumbed to EV71 infection when challenged with EV71 infection twice. In addition, abnormal symptoms were demonstrated in the survivors and their progenies. Based on the serum chemokine/cytokine detection performed, potent immunological stress was likely responsible for this lethality and teratogenicity, not the infectivity and virulence of EV71. Active EV71 challenge resulted in more serious lethality and teratogenicity compared with inactive EV71 challenge. However, the mechanisms underlying this effect of EV71 require further research. Furthermore, the neutralizing antibody in maternal mice and their offspring was present over a long period of time at a high titer when the mice were challenged twice. These results indicate that EV71 exhibits notable immunogenicity, suggesting its suitability as a potential vaccine candidate. In addition, the presence of the maternal antibody in the fetus was revealed to be protective against EV71-induced mortality, which suggests that children <5 years old and women of child-bearing age may benefit from receiving EV71 vaccination.
The majority of previous studies have reported that adult mice are not susceptible to EV71 infection, with only suckling mice able to be infected by EV71. To the best of our knowledge, the present study is the first to report that active EV71 challenge inhibits the reproductive capacity of female mice, and induces neurologic symptoms in adults and offspring. In humans, occult EV71 infection is common in adults without any symptoms (2), who may act as a reservoir host for susceptible infants. Furthermore, if a woman of childbearing age is infected with EV71, little is known about whether this infection would harm to her fetus. Thus, further studies warranted to investigate this effect of EV71 in humans.
In conclusion, a novel challenge method of EV71, hydrodynamic injection, was established in the present study. Due to the higher titer of EV71 in the tissue of challenged mice, it was demonstrated to be more effective than intraperitoneal injection. Generally speaking, EV71 infection was only fatal to suckling mice within 7 days of birth. In the present study, a higher rate of teratogenesis occurred in adult mice following EV71 infection. In particular, the twice-active EV71 challenge may cause mortality in adult mice, and surviving mice have a significantly lower reproductive capacity. These results suggest that occult EV71 infection in humans, in particular women of childbearing age, may pose a serious health risk.
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